Perosphere Technologies has signed an agreement with M3 Medical, a distributor under Uniphar Medtech, to distribute its point-of-care (PoC) coagulometer, Perosphere ClotChek, across Ireland.
Perosphere ClotChek is a hand-held device that is designed to deliver rapid, precise data for informed medical decisions.
The device, equipped with a colour touch screen, and barcode reader, is said to be the only pharmacodynamic, reagent-free diagnostic tool designed for bedside use.
Its rapid test results enable health care professionals (HCPs) to swiftly diagnose coagulation status, facilitating informed treatment decisions in emergency and other medical scenarios.
The PoC coagulometer delivers diagnostic outcomes within three to eight minutes, aiding HCPs in prompt patient management.
The tool is capable of rapidly and accurately testing clotting times across various drug classes, including direct oral anticoagulants (DOACs).
It supports healthcare providers in managing patients on anticoagulant therapies or those at risk of bleeding.
In 2021, Perosphere ClotChek received the CE Mark in the European Union.
The latest distribution agreement makes Ireland the first country to introduce Perosphere Technologies’ coagulometer into hospitals and healthcare facilities.
Perosphere Technologies chief operating officer Daryl Mootoo said: “We are excited to partner with M3 Medical based on the company’s longstanding expertise and demonstrated success in the medical device market to improve patient care.
“We trust in M3 Medical’s capabilities to bring Perosphere ClotChek to healthcare providers in Ireland and help us change the current standard of testing and care in anticoagulation management.”
M3 Medical is an Irish distributor of medical devices specialising in interventional cardiology, radiology, neuroradiology, vascular surgery, and cardiac rhythm management across Ireland and the UK.
It operates as part of Uniphar Medtech, a European distributor of medical devices headquartered in Ireland, with operations spanning 21 markets.
M3 Medical Ireland business unit leader Robbie Dolan said: “We recognise the value of Perosphere ClotChek, a unique coagulation testing device, especially in Ireland given the widespread use of anticoagulants and the unmet need for fast and complete coagulation diagnosis.
“We are proud to enter into this exclusive agreement in order to help improve patient outcomes and reduce health system costs in Ireland.”
